Risperidone

is prescribed to treat:

• Schizophrenia in adults and adolescents (13+) • Bipolar I disorder (acute manic or mixed episodes) • Irritability associated with autistic disorder in children (5-16 years) • Major depressive disorder (adjunctive treatment - off-label)

It helps reduce hallucinations, delusions, and mood symptoms.

Risperidone (Risperdal) is an atypical antipsychotic used for schizophrenia, for acute mania in bipolar disorder, and for irritability associated with autism. It was among the first of the atypicals and remains widely used, distinguished within the class by strong dopamine blockade — which delivers reliable antipsychotic efficacy at the cost of the most prominent extrapyramidal and prolactin effects of the modern agents.

Mechanism of Action

Risperidone antagonises dopamine D2 and serotonin 5-HT2A receptors. The 5-HT2A component is what defines an atypical antipsychotic and moderates the movement side effects that dominated the older typical agents.

Risperidone's D2 blockade is nonetheless potent and tightly binding compared with, for instance, quetiapine, whose loose and rapidly dissociating D2 binding produces far fewer movement effects. The consequence is that risperidone behaves in a dose-dependent way: at lower doses it is genuinely atypical, while at higher doses D2 occupancy reaches the range where extrapyramidal symptoms and tardive dyskinesia become as likely as with a typical antipsychotic. Dose restraint is therefore not a minor consideration but the central one.

Dopamine blockade in the tuberoinfundibular pathway also removes dopamine's normal inhibition of prolactin release, and risperidone raises prolactin more than any other commonly used atypical. The resulting hyperprolactinemia causes menstrual irregularity, galactorrhoea, sexual dysfunction, gynecomastia, and — with prolonged elevation — reduced bone density. This is frequently under-recognised because the symptoms are not volunteered.

Alpha-1 blockade produces orthostatic hypotension, which is why titration is gradual.

Clinical Use

Risperidone is effective in schizophrenia and in acute mania, and it is one of the few antipsychotics with an approved indication for irritability in autism, where it is used at low doses in children and adolescents.

A long-acting injectable formulation exists and is genuinely valuable in patients whose illness relapses because of inconsistent oral adherence — a common and consequential pattern in schizophrenia, where each relapse carries functional cost that is not fully recovered.

Compared with other atypicals, risperidone sits in the middle of the metabolic risk range: less weight gain than olanzapine or quetiapine, more than aripiprazole or ziprasidone. Where prolactin effects or movement symptoms are the limiting problem, aripiprazole is the usual alternative, since it is a partial dopamine agonist and actually lowers prolactin.

As with the class, risperidone is sometimes prescribed off-label for agitation in dementia, insomnia, or non-psychotic anxiety. The boxed warning about mortality in elderly patients with dementia-related psychosis makes the first of these a decision requiring explicit justification rather than routine use. Our psychiatric team manages these regimens, and the MedlinePlus risperidone entry covers prescribing detail.

Monitoring and Follow-Up

Metabolic monitoring applies across the antipsychotic class and is frequently neglected. Record weight and BMI at baseline and track them; check waist circumference, fasting glucose or hemoglobin A1c, and a lipid panel at baseline, at three months, and at least annually thereafter.

Movement examination is a specific requirement with risperidone given its D2 potency. Extrapyramidal symptoms — rigidity, tremor, bradykinesia, akathisia — can emerge early and are dose-related, while tardive dyskinesia develops over months to years and may become permanent if the drug is continued once it appears. Structured assessment at regular intervals detects it earlier than casual observation does. Akathisia in particular is often mistaken for worsening agitation and treated with a dose increase, which makes it worse.

Prolactin should be checked when symptoms suggest elevation, and considered proactively given how rarely patients raise sexual or menstrual symptoms unprompted. Prolonged elevation warrants attention to bone health — the bone health article covers the broader picture.

Blood pressure should be checked sitting and standing during titration. Risperidone is metabolised by CYP2D6, so inhibitors including fluoxetine, paroxetine, and bupropion raise levels meaningfully. The National Institute of Mental Health provides patient-level background.

The long-acting injectable deserves more consideration than it usually receives, and not only for patients with poor adherence. It removes the daily decision to take a medication that many people with schizophrenia feel ambivalent about, produces steadier levels without the peaks that drive side effects, and makes non-adherence visible as a missed appointment rather than as an unnoticed slide toward relapse. It is often framed as a measure of last resort for difficult patients, which understates it — some patients simply prefer it, and offering it as an option rather than a consequence changes how it is received.

Switching between antipsychotics is also more common than staying on the first choice indefinitely, and it is done by cross-titration rather than by stopping one and starting another. A patient whose limiting problem is prolactin elevation, weight gain, or movement symptoms has real alternatives within the class, and none of those side effects is a reason to abandon antipsychotic treatment altogether.

Special Populations

Antipsychotics carry a boxed warning of increased mortality in elderly patients with dementia-related psychosis, and risperidone is not approved for that use. Where behavioural symptoms genuinely require medication after non-pharmacologic approaches have failed, the lowest dose for the shortest period with documented justification is the standard.

In older adults generally, start low given orthostatic hypotension, falls, and heightened extrapyramidal sensitivity. Both hepatic and renal impairment require dose reduction. In pregnancy it is used when the psychiatric indication warrants, since untreated severe mental illness carries substantial risk; risperidone is among the better-studied antipsychotics in pregnancy.

When to Contact Your Doctor

Seek emergency care for high fever with muscle rigidity, confusion, and autonomic instability, which suggests neuroleptic malignant syndrome.

Report uncontrollable movements of the face, tongue, or limbs, which may indicate tardive dyskinesia — early detection matters because continuing the drug can make it permanent. Report inner restlessness or an inability to sit still, which is akathisia and needs a dose reduction rather than an increase. Report new stiffness, tremor, or slowed movement.

Report menstrual changes, breast enlargement or discharge, or sexual dysfunction — these are common, treatable, and rarely volunteered. Report substantial weight gain, increased thirst, or increased urination. Fainting or near-fainting warrants review of the dose and titration.

To review your dose, your metabolic and movement monitoring, or side effects that are making treatment hard to continue, contact us or schedule a visit.